<p>湯普森·戴維斯公司在第二季度收購了 CVS Health Corporation（紐約證券交易所代碼：CVS - 免費報告）的新股份，根據其最近向證券交易委員會（SEC）提交的 13F 表格。該機構投資者收購了 16,529 股該藥房運營商的股票，價值約為 1,140,000 美元。</p>
<ul>
<li>CVS Health 因收入增長而上漲，股息保持強勁</li>
</ul>
<p>其他幾家對沖基金和機構投資者也調整了對 CVS 的持股。FineMark 國家銀行和信託在第二季度將其在 CVS Health 的持股增加了 1.7%。FineMark 國家銀行和信託目前擁有 9,576 股該藥房運營商的股票，價值 661,000 美元，在此期間又收購了 157 股。Smartleaf 資產管理公司在第二季度將其在 CVS Health 的股份增加了 1.1%。Smartleaf 資產管理公司目前擁有 15,059 股該藥房運營商的股票，價值 1,031,000 美元，在上個季度又購買了 164 股。Hazlett Burt &amp; Watson 公司在第二季度將其在 CVS Health 的股份增加了 10.9%。Hazlett Burt &amp; Watson 公司目前擁有 1,682 股該藥房運營商的股票，價值 117,000 美元，在此期間又購買了 165 股。Loomis Sayles &amp; Co. L P 在第二季度將其在 CVS Health 的持股增加了 11.0%。Loomis Sayles &amp; Co. L P 目前擁有 1,674 股該藥房運營商的股票，價值 115,000 美元，在上個季度又購買了 166 股。最後，Williams Financial LLC 在第二季度將其在 CVS Health 的股份增加了 2.5%。Williams Financial LLC 目前擁有 6,923 股該藥房運營商的股票，價值 478,000 美元，在此期間又購買了 167 股。機構投資者持有該公司 80.66% 的股份。</p>
<h2>CVS Health 股票表現</h2>
<p>CVS Health 的股票在週五開盤價為 79.45 美元。該公司的流動比率為 0.83，速動比率為 0.63，債務與股本比率為 0.83。該公司的市值為 1,008.5 億美元，市盈率為 209.08，市盈率增長比率為 0.78，貝塔值為 0.48。該公司的 50 日移動平均線為 78.97 美元，200 日移動平均線為 71.91 美元。CVS Health Corporation 的 1 年最低價為 43.56 美元，1 年最高價為 85.15 美元。</p>
<ul>
<li>MarketBeat 週迴顧 – 05/12 - 05/16</li>
</ul>
<p>CVS Health（紐約證券交易所代碼：CVS - 獲取免費報告）最近於 10 月 29 日（星期三）公佈了季度財報。該藥房運營商報告每股收益（EPS）為 1.60 美元，超出分析師一致預期的 1.36 美元，超出幅度為 0.24 美元。CVS Health 的淨利潤率為 0.12%，股本回報率為 11.45%。該公司本季度的收入為 1,028.7 億美元，而分析師預期為 988.5 億美元。去年同期，該公司每股收益為 1.09 美元。該公司的季度收入同比增長 7.8%。CVS Health 已將其 2025 財年的指導目標設定為 6.550-6.650 EPS。作為一個整體，股票研究分析師預測 CVS Health Corporation 在當前財年將發佈 5.89 的每股收益。</p>
<h2>CVS Health 股息公告</h2>
<p>該公司最近還披露了季度股息，該股息於 11 月 3 日（星期一）支付。10 月 23 日（星期四）的登記投資者獲得了 0.665 美元的股息。該股息的除息日期為 10 月 23 日（星期四）。這代表着每年 2.66 美元的股息和 3.3% 的收益率。CVS Health 的股息支付比率（DPR）為 700.00%。</p>
<h2>華爾街分析師觀點</h2>
<ul>
<li>現在是購買 Novo Nordisk 股票的時機嗎？</li>
</ul>
<p>一些股票研究分析師最近對該公司發表了看法。桑福德·C·伯恩斯坦在週五將 CVS Health 的目標價從 86.00 美元上調至 87.00 美元，並給予該股票 “市場表現” 評級。瑞銀集團在週三重申了對 CVS Health 股票的 “跑贏大盤” 評級。瑞穗證券在週三將 CVS Health 股票的目標價從 88.00 美元上調至 95.00 美元，並給予該公司 “跑贏大盤” 評級。摩根士丹利在週三將 CVS Health 股票的目標價從 89.00 美元上調至 93.00 美元，並給予該股票 “增持” 評級。最後，Leerink Partners 在 10 月 16 日（星期四）將 CVS Health 的目標價從 86.00 美元上調至 95.00 美元，並給予該公司 “跑贏大盤” 評級。兩位分析師對該股票給予了強烈買入評級，二十位分析師給予了買入評級，四位分析師對該公司給予了持有評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “適度買入”，共識目標價為 93.71 美元。</p>
<p><strong>查看我們關於 CVS 的最新研究報告</strong></p>
<h2>CVS Health 公司簡介</h2>
<p>（免費報告）</p>
<p>CVS Health Corporation 在美國提供健康解決方案。它通過醫療保險、健康服務和藥房及消費者健康三個部門運營。醫療保險部門提供傳統、自願和消費者導向的健康保險產品及相關服務。</p>
<h2>另請參閲</h2>
<ul>
<li>我們更看好的五隻股票超過 CVS Health</li>
<li>除息日對投資者的重要性是什麼？</li>
<li>迪士尼的 10 億美元交易將其魔力帶入 OpenAI</li>
<li>投資石油股票的方式和原因</li>
<li>為什麼亞馬遜可能在幾周內成為 300 美元的股票</li>
<li>什麼是股息？購買最佳股息股票</li>
<li>Adobe 在財報後獲得提振：長期前景看漲</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 CVS Health 嗎？</h2>
<p>在考慮 CVS Health 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 CVS Health 並不在名單上。</p>
<p>雖然 CVS Health 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

西維斯

<p>Thompson Davis & CO. Inc. 在第二季度投資了 114 萬美元於 CVS Health Corporation，購買了 16,529 股。其他機構投資者也調整了他們的持股。CVS Health 報告了強勁的季度收益，超出預期，每股收益為 1.60 美元，收入為 1028.7 億美元。分析師提高了目標價格，評級範圍從 “市場表現” 到 “跑贏大盤”。CVS Health 的股息收益率為 3.3%，派息比率為 700%。機構投資者持有 CVS 股票的 80.66%</p>

<p>Thompson Davis &amp; CO. Inc. acquired a new stake in CVS Health Corporation (NYSE:CVS - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,529 shares of the pharmacy operator's stock, valued at approximately $1,140,000.</p>
<div class="lb-trans"><p>湯普森·戴維斯公司在第二季度收購了 CVS Health Corporation（紐約證券交易所代碼：CVS - 免費報告）的新股份，根據其最近向證券交易委員會（SEC）提交的 13F 表格。該機構投資者收購了 16,529 股該藥房運營商的股票，價值約為 1,140,000 美元。</p>
</div><ul>
<li>CVS Health Gains as Revenue Grows, Dividend Remains Strong</li>
</ul>
<div class="lb-trans"><ul>
<li>CVS Health 因收入增長而上漲，股息保持強勁</li>
</ul>
</div><p>Several other hedge funds and other institutional investors have also modified their holdings of CVS. FineMark National Bank &amp; Trust raised its holdings in CVS Health by 1.7% in the 2nd quarter. FineMark National Bank &amp; Trust now owns 9,576 shares of the pharmacy operator's stock valued at $661,000 after acquiring an additional 157 shares during the period. Smartleaf Asset Management LLC grew its position in shares of CVS Health by 1.1% in the second quarter. Smartleaf Asset Management LLC now owns 15,059 shares of the pharmacy operator's stock valued at $1,031,000 after purchasing an additional 164 shares during the last quarter. Hazlett Burt &amp; Watson Inc. increased its stake in shares of CVS Health by 10.9% during the second quarter. Hazlett Burt &amp; Watson Inc. now owns 1,682 shares of the pharmacy operator's stock worth $117,000 after purchasing an additional 165 shares during the period. Loomis Sayles &amp; Co. L P lifted its holdings in CVS Health by 11.0% during the 2nd quarter. Loomis Sayles &amp; Co. L P now owns 1,674 shares of the pharmacy operator's stock worth $115,000 after purchasing an additional 166 shares during the last quarter. Finally, Williams Financial LLC boosted its stake in CVS Health by 2.5% in the 2nd quarter. Williams Financial LLC now owns 6,923 shares of the pharmacy operator's stock valued at $478,000 after purchasing an additional 167 shares during the period. Institutional investors own 80.66% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家對沖基金和機構投資者也調整了對 CVS 的持股。FineMark 國家銀行和信託在第二季度將其在 CVS Health 的持股增加了 1.7%。FineMark 國家銀行和信託目前擁有 9,576 股該藥房運營商的股票，價值 661,000 美元，在此期間又收購了 157 股。Smartleaf 資產管理公司在第二季度將其在 CVS Health 的股份增加了 1.1%。Smartleaf 資產管理公司目前擁有 15,059 股該藥房運營商的股票，價值 1,031,000 美元，在上個季度又購買了 164 股。Hazlett Burt &amp; Watson 公司在第二季度將其在 CVS Health 的股份增加了 10.9%。Hazlett Burt &amp; Watson 公司目前擁有 1,682 股該藥房運營商的股票，價值 117,000 美元，在此期間又購買了 165 股。Loomis Sayles &amp; Co. L P 在第二季度將其在 CVS Health 的持股增加了 11.0%。Loomis Sayles &amp; Co. L P 目前擁有 1,674 股該藥房運營商的股票，價值 115,000 美元，在上個季度又購買了 166 股。最後，Williams Financial LLC 在第二季度將其在 CVS Health 的股份增加了 2.5%。Williams Financial LLC 目前擁有 6,923 股該藥房運營商的股票，價值 478,000 美元，在此期間又購買了 167 股。機構投資者持有該公司 80.66% 的股份。</p>
</div><h2>CVS Health Stock Performance</h2>
<div class="lb-trans"><h2>CVS Health 股票表現</h2>
</div><p>Shares of CVS Health stock opened at $79.45 on Friday. The company has a current ratio of 0.83, a quick ratio of 0.63 and a debt-to-equity ratio of 0.83. The company has a market cap of $100.85 billion, a PE ratio of 209.08, a price-to-earnings-growth ratio of 0.78 and a beta of 0.48. The company has a 50 day moving average of $78.97 and a 200-day moving average of $71.91. CVS Health Corporation has a 1-year low of $43.56 and a 1-year high of $85.15.</p>
<div class="lb-trans"><p>CVS Health 的股票在週五開盤價為 79.45 美元。該公司的流動比率為 0.83，速動比率為 0.63，債務與股本比率為 0.83。該公司的市值為 1,008.5 億美元，市盈率為 209.08，市盈率增長比率為 0.78，貝塔值為 0.48。該公司的 50 日移動平均線為 78.97 美元，200 日移動平均線為 71.91 美元。CVS Health Corporation 的 1 年最低價為 43.56 美元，1 年最高價為 85.15 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 05/12 - 05/16</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 05/12 - 05/16</li>
</ul>
</div><p>CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.36 by $0.24. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The business had revenue of $102.87 billion for the quarter, compared to analysts' expectations of $98.85 billion. During the same period last year, the firm posted $1.09 earnings per share. The firm's quarterly revenue was up 7.8% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. As a group, equities research analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>CVS Health（紐約證券交易所代碼：CVS - 獲取免費報告）最近於 10 月 29 日（星期三）公佈了季度財報。該藥房運營商報告每股收益（EPS）為 1.60 美元，超出分析師一致預期的 1.36 美元，超出幅度為 0.24 美元。CVS Health 的淨利潤率為 0.12%，股本回報率為 11.45%。該公司本季度的收入為 1,028.7 億美元，而分析師預期為 988.5 億美元。去年同期，該公司每股收益為 1.09 美元。該公司的季度收入同比增長 7.8%。CVS Health 已將其 2025 財年的指導目標設定為 6.550-6.650 EPS。作為一個整體，股票研究分析師預測 CVS Health Corporation 在當前財年將發佈 5.89 的每股收益。</p>
</div><h2>CVS Health Dividend Announcement</h2>
<div class="lb-trans"><h2>CVS Health 股息公告</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Investors of record on Thursday, October 23rd were paid a $0.665 dividend. The ex-dividend date of this dividend was Thursday, October 23rd. This represents a $2.66 annualized dividend and a yield of 3.3%. CVS Health's dividend payout ratio (DPR) is 700.00%.</p>
<div class="lb-trans"><p>該公司最近還披露了季度股息，該股息於 11 月 3 日（星期一）支付。10 月 23 日（星期四）的登記投資者獲得了 0.665 美元的股息。該股息的除息日期為 10 月 23 日（星期四）。這代表着每年 2.66 美元的股息和 3.3% 的收益率。CVS Health 的股息支付比率（DPR）為 700.00%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><ul>
<li>Is It Time to Buy the Dip in Novo Nordisk Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>現在是購買 Novo Nordisk 股票的時機嗎？</li>
</ul>
</div><p>A number of equities research analysts have recently weighed in on the company. Sanford C. Bernstein lifted their target price on CVS Health from $86.00 to $87.00 and gave the stock a &#34;market perform&#34; rating in a report on Friday. UBS Group reiterated an &#34;outperform&#34; rating on shares of CVS Health in a research note on Wednesday. Mizuho boosted their price objective on shares of CVS Health from $88.00 to $95.00 and gave the company an &#34;outperform&#34; rating in a report on Wednesday. Morgan Stanley raised their target price on shares of CVS Health from $89.00 to $93.00 and gave the stock an &#34;overweight&#34; rating in a report on Wednesday. Finally, Leerink Partners boosted their price target on CVS Health from $86.00 to $95.00 and gave the company an &#34;outperform&#34; rating in a research note on Thursday, October 16th. Two analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $93.71.</p>
<div class="lb-trans"><p>一些股票研究分析師最近對該公司發表了看法。桑福德·C·伯恩斯坦在週五將 CVS Health 的目標價從 86.00 美元上調至 87.00 美元，並給予該股票 “市場表現” 評級。瑞銀集團在週三重申了對 CVS Health 股票的 “跑贏大盤” 評級。瑞穗證券在週三將 CVS Health 股票的目標價從 88.00 美元上調至 95.00 美元，並給予該公司 “跑贏大盤” 評級。摩根士丹利在週三將 CVS Health 股票的目標價從 89.00 美元上調至 93.00 美元，並給予該股票 “增持” 評級。最後，Leerink Partners 在 10 月 16 日（星期四）將 CVS Health 的目標價從 86.00 美元上調至 95.00 美元，並給予該公司 “跑贏大盤” 評級。兩位分析師對該股票給予了強烈買入評級，二十位分析師給予了買入評級，四位分析師對該公司給予了持有評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “適度買入”，共識目標價為 93.71 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on CVS</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 CVS 的最新研究報告</strong></p>
</div><h2>CVS Health Company Profile</h2>
<div class="lb-trans"><h2>CVS Health 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy &amp; Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.</p>
<div class="lb-trans"><p>CVS Health Corporation 在美國提供健康解決方案。它通過醫療保險、健康服務和藥房及消費者健康三個部門運營。醫療保險部門提供傳統、自願和消費者導向的健康保險產品及相關服務。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than CVS Health</li>
<li>Why is the Ex-Dividend Date Significant to Investors?</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
<li>The How And Why of Investing in Oil Stocks</li>
<li>Why Amazon Could Be a $300 Stock Within Weeks</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 CVS Health</li>
<li>除息日對投資者的重要性是什麼？</li>
<li>迪士尼的 10 億美元交易將其魔力帶入 OpenAI</li>
<li>投資石油股票的方式和原因</li>
<li>為什麼亞馬遜可能在幾周內成為 300 美元的股票</li>
<li>什麼是股息？購買最佳股息股票</li>
<li>Adobe 在財報後獲得提振：長期前景看漲</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=CVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CVS Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 CVS Health 嗎？</h2>
</div><p>Before you consider CVS Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 CVS Health 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 CVS Health 並不在名單上。</p>
</div><p>While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 CVS Health 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Thompson Davis & CO. Inc. 對 CVS Health Corporation（西維斯公司）進行了新的 114 萬美元投資